[go: up one dir, main page]

PL2343380T3 - Wymiana kasety dla regionu zmiennego immunoglobuliny - Google Patents

Wymiana kasety dla regionu zmiennego immunoglobuliny

Info

Publication number
PL2343380T3
PL2343380T3 PL10014128T PL10014128T PL2343380T3 PL 2343380 T3 PL2343380 T3 PL 2343380T3 PL 10014128 T PL10014128 T PL 10014128T PL 10014128 T PL10014128 T PL 10014128T PL 2343380 T3 PL2343380 T3 PL 2343380T3
Authority
PL
Poland
Prior art keywords
variable region
immunoglobulin variable
cassette exchange
region cassette
exchange
Prior art date
Application number
PL10014128T
Other languages
English (en)
Inventor
Christopher Bebbington
Kenneth Luehrsen
Geoffrey Yarranton
Original Assignee
Humanigen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36407771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2343380(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humanigen, Inc. filed Critical Humanigen, Inc.
Publication of PL2343380T3 publication Critical patent/PL2343380T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL10014128T 2004-11-16 2005-11-16 Wymiana kasety dla regionu zmiennego immunoglobuliny PL2343380T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US62858104P 2004-11-16 2004-11-16
EP05851809.3A EP1824987B1 (en) 2004-11-16 2005-11-16 Immunoglobulin variable region cassette exchange
EP10014128.2A EP2343380B1 (en) 2004-11-16 2005-11-16 Immunoglobulin variable region cassette exchange
PCT/US2005/041825 WO2006055778A2 (en) 2004-11-16 2005-11-16 Immunoglobulin variable region cassette exchange

Publications (1)

Publication Number Publication Date
PL2343380T3 true PL2343380T3 (pl) 2020-03-31

Family

ID=36407771

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19169135T PL3540062T3 (pl) 2004-11-16 2005-11-16 Wymiana kasety dla regionu zmiennego immunoglobuliny
PL10014128T PL2343380T3 (pl) 2004-11-16 2005-11-16 Wymiana kasety dla regionu zmiennego immunoglobuliny

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19169135T PL3540062T3 (pl) 2004-11-16 2005-11-16 Wymiana kasety dla regionu zmiennego immunoglobuliny

Country Status (10)

Country Link
US (2) US20060134098A1 (pl)
EP (3) EP2343380B1 (pl)
JP (1) JP2008520586A (pl)
AU (1) AU2005306502B2 (pl)
CA (1) CA2587158C (pl)
DK (2) DK2343380T3 (pl)
ES (3) ES2881353T3 (pl)
PL (2) PL3540062T3 (pl)
PT (2) PT3540062T (pl)
WO (1) WO2006055778A2 (pl)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
PL3540062T3 (pl) 2004-11-16 2021-12-27 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
BRPI0618160A2 (pt) * 2005-05-26 2011-08-16 Univ Colorado inibição da via alternativa complemento para tratamento de danos cerebrais traumáticos, danos na medula espinhal e condições relacionadas
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US20080171038A1 (en) * 2006-11-08 2008-07-17 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
CA2670288C (en) 2006-11-21 2015-10-27 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
CA2678451A1 (en) * 2007-02-20 2008-08-28 Robert A. Horlick Somatic hypermutation systems
ES2910298T3 (es) 2007-03-08 2022-05-12 Humanigen Inc Anticuerpos contra EphA3 para el tratamiento de tumores sólidos
WO2008140653A2 (en) * 2007-03-14 2008-11-20 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
CA2693201A1 (en) * 2007-07-17 2009-01-22 Irm Llc Antagonist antibodies of protease activated receptor-1 (par1)
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
NZ586357A (en) * 2007-11-30 2012-10-26 Kalobios Pharmaceuticals Inc Antibodies to the pcrv antigen of pseudomonas aeruginosa
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
PT2281078E (pt) 2008-04-24 2015-02-05 Dyax Corp Bibliotecas de pacotes genéticos compreendendo desenhos de novas cdr1, cdr2, e cdr3 de hc e novas cdr1, cr2, e cdr3 de lc
AU2009243184B2 (en) * 2008-04-28 2015-06-04 Humanigen, Inc. Antibodies to granulocyte-macrophage colony-stimulating factor
CA2751433A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection
US9079942B2 (en) 2009-02-09 2015-07-14 Epitomics, Inc. CDR-anchored amplification method
WO2010093814A1 (en) 2009-02-11 2010-08-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a gm-csf antagonist
EA201101241A1 (ru) 2009-03-06 2012-04-30 Калобайос Фармасьютиклз, Инк. Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
US8921281B2 (en) * 2009-05-20 2014-12-30 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
US8293483B2 (en) 2009-09-11 2012-10-23 Epitomics, Inc. Method for identifying lineage-related antibodies
JP2013508292A (ja) * 2009-10-14 2013-03-07 カロバイオス ファーマシューティカルズ インコーポレイティッド ＥｐｈＡ３に対する抗体
AR079336A1 (es) * 2009-12-11 2012-01-18 Irm Llc Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
AU2010335283B2 (en) * 2009-12-22 2016-01-14 F. Hoffmann-La Roche Ag Sequence dependent aggregation
MX342270B (es) 2010-02-18 2016-09-21 The Regents Of The Univ Of California * ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8.
CA2794851A1 (en) * 2010-04-02 2011-10-06 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest
EA201391157A1 (ru) 2011-02-11 2014-02-28 АйАрЭм ЭлЭлСи Антагонисты pcsk9
EP3798236B1 (en) * 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
WO2012168491A1 (en) 2011-06-10 2012-12-13 Novartis Ag Pharmaceutical formulations of pcsk9 antagonists
WO2012170607A2 (en) 2011-06-10 2012-12-13 Novartis Ag Use of pcsk9 antagonists
WO2013052582A2 (en) * 2011-10-05 2013-04-11 Kalobios Pharmaceuticals, Inc. Generation of antibodies to an epitope of interest that contains a phosphomimetic amino acid
US9790280B2 (en) 2011-10-26 2017-10-17 Elanco Tiergesundheit Ag Monoclonal canine CD20 antibodies and methods of use
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
KR102311761B1 (ko) 2013-12-09 2021-10-13 알라코스 인크. 항-Siglec-8 항체 및 그의 사용 방법
US10183996B2 (en) 2014-02-28 2019-01-22 Allakos Inc. Methods and compositions for treating Siglec-8 associated diseases
CA2943588C (en) * 2014-06-17 2019-04-30 Academia Sinica Humanized anti-ige antibodies that crosslink cd23 on b lymphocytes but do not sensitize mast cells
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP6846362B2 (ja) 2015-06-17 2021-03-24 アラコス インコーポレイテッド 線維性疾患を処置するための方法および組成物
US10604577B2 (en) 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
MA43372A (fr) 2015-12-04 2018-10-10 Novartis Ag Compositions à greffe de cytokine-anticorps et procédés d'utilisation pour l'immunorégulation
US11052111B2 (en) 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
WO2018053032A1 (en) 2016-09-13 2018-03-22 Humanigen, Inc. Epha3 antibodies for the treatment of pulmonary fibrosis
EP3532496A1 (en) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
EP3618868A4 (en) 2017-05-05 2021-02-24 Allakos Inc. METHODS AND COMPOSITIONS FOR TREATING ALLERGIC EYE DISEASES
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
JP7320498B2 (ja) 2017-10-02 2023-08-03 ヒューマニジェン，インコーポレイテッド Ｇｍ－ｃｓｆアンタゴニストを使用した免疫療法関連毒性の治療方法
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
SG11202106498XA (en) 2018-12-26 2021-07-29 Xilio Development Inc Anti-ctla4 antibodies and methods of use thereof
US20220340662A1 (en) 2021-03-01 2022-10-27 Xilio Development, Inc. Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
TW202317612A (zh) 2021-03-01 2023-05-01 美商艾希利歐發展股份有限公司 用於治療癌症的ｃｔｌａ４及ｐｄ１／ｐｄｌ１抗體之組合

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3742105A (en) 1970-05-05 1973-06-26 S Kuroda Method for producing a seamless tubing
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
ES2052027T5 (es) * 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6969586B1 (en) * 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992015683A1 (en) 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
PT859841E (pt) * 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
ATE531812T1 (de) * 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
US6875590B2 (en) 2000-06-05 2005-04-05 Corixa Corporation Leader peptides for enhancing secretion of recombinant protein from a host cell
AU2001268545A1 (en) 2000-06-21 2002-01-08 Alexion Pharmaceuticals, Inc. Libraries displaying human antibody fragments with hybrid complementarity determining regions
EP2298809A3 (en) 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20030219839A1 (en) * 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
AU2003248548B2 (en) * 2002-05-20 2010-03-11 Abmaxis, Inc. Generation and selection of protein library in silico
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
WO2004072266A2 (en) * 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
EP1761561B1 (en) * 2004-01-20 2015-08-26 KaloBios Pharmaceuticals, Inc. Antibody specificity transfer using minimal essential binding determinants
BRPI0516962A (pt) 2004-10-25 2008-09-30 Univ Northwestern anticorpo isolado, ou fragmento do mesmo, composição farmacêutica, métodos para prevenir a ligação de ligantes difundìveis derivados de abeta a um neurÈnio, para inibir a constituição de ligantes difundìveis, para bloquear a fosforilação de proteìna, para tratar profilaticamente ou terapeuticamente uma doença, para identificar um agente terapêutico, para detectar ligantes difundìveis, e para diagnosticar uma doença, e, kit para detectar ligantes difundìveis
PL3540062T3 (pl) 2004-11-16 2021-12-27 Humanigen, Inc. Wymiana kasety dla regionu zmiennego immunoglobuliny
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof

Also Published As

Publication number Publication date
ES2429541T3 (es) 2013-11-15
EP2343380B1 (en) 2019-06-12
US20160102152A1 (en) 2016-04-14
EP3540062A1 (en) 2019-09-18
PT3540062T (pt) 2021-07-06
EP3540062B1 (en) 2021-05-12
ES2881353T3 (es) 2021-11-29
PT2343380T (pt) 2019-09-18
PL3540062T3 (pl) 2021-12-27
WO2006055778A2 (en) 2006-05-26
CA2587158C (en) 2016-01-12
AU2005306502A1 (en) 2006-05-26
DK2343380T3 (da) 2019-09-09
EP2343380A1 (en) 2011-07-13
US10919983B2 (en) 2021-02-16
ES2744149T3 (es) 2020-02-21
CA2587158A1 (en) 2006-05-26
DK3540062T3 (da) 2021-06-28
JP2008520586A (ja) 2008-06-19
AU2005306502B2 (en) 2012-11-15
EP1824987B1 (en) 2013-08-21
WO2006055778A3 (en) 2006-11-23
EP1824987A4 (en) 2008-03-19
EP1824987A2 (en) 2007-08-29
US20060134098A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
PL3540062T3 (pl) Wymiana kasety dla regionu zmiennego immunoglobuliny
TWI307630B (en) Immunoglobulins
TWI365746B (en) Immunoglobulins
EP1789217A4 (en) SANDWICH FINS
IL183861A0 (en) Temperature compensanon
GB0423303D0 (en) No title
GB0426735D0 (en) The mobile e-commerce exchange
GB0417789D0 (en) Access control
GB0407231D0 (en) Variable lens
GB0423010D0 (en) Cassette
ZA200504313B (en) Cassette assembly
GB2410544B (en) Radiator cover
ZA200610612B (en) Immunoglobulins
GB0302699D0 (en) Immunoglobulin
GB0417389D0 (en) No title
GB0417492D0 (en) Radiator covers
GB0407197D0 (en) Immunoglobulins
GB0405968D0 (en) Neat heat
GB0513766D0 (en) Immunoglobulins
PL1635122T3 (pl) Grzejnik
GB0407193D0 (en) Immunoglobulins
GB0423675D0 (en) Immunoglobulins
GB0401247D0 (en) Router cassette
AU2004905263A0 (en) Heat exchanger improvements
AU2004906517A0 (en) Heat exchanger improvements